MNKD (MannKind) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MNKD MannKind Corp MNKD
66 GF Score
Price $4.26
GF Value $7.40
Valuation Possible Value Trap
! 8 Warning Signs
View Full Analysis

What is MannKind Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

MNKD
66GF Score
MannKind Corp MNKD
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is MannKind (MNKD) Overvalued in 2026?

Based on GuruFocus' analysis, MannKind stock appears to be undervalued. The current stock price of $4.26 is trading 42.4% below its estimated GF Value™ of $7.40. GuruFocus considers MannKind to be Possible Value Trap.

Key valuation signals for MNKD:

  • Interest Received:
  • GF Value™: $7.40 vs. price of $4.26 (42.4% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the MNKD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MannKind Business Description

Other Exchanges NNFN:Germany
Address 1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
66GF Score

Get the complete analysis for MNKD

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.26
Price
$7.40
GF Value